Stanley Capital

Stanley Capital is a private equity investment firm based in London, United Kingdom, founded in 2019. The firm specializes in pursuing repeatable relative value and thematic investment strategies, focusing on sectors such as technology, healthcare, and sustainability. By targeting businesses within these industries, Stanley Capital aims to drive growth and create value through its investment initiatives across Europe.

Simon Cottle

Founding Partner

Patrick Hargutt

Founding Partner

3 past transactions

SePRO

Acquisition in 2024
SePRO Corporation is a manufacturer of sustainable specialty chemicals focused on plant protection and management. The company develops a range of products for various sectors, including pro-aquatic, agriculture, landscape, ornamental, golf, and DIY aquatics. Their offerings encompass plant growth regulators, herbicides, insecticides, and fungicides, which are designed to help manage invasive weeds and algae in both terrestrial and aquatic environments. SePRO's commitment to innovation enables it to address the specific needs of its key markets effectively.

Roboyo

Private Equity Round in 2023
Roboyo GmbH is an automation consulting company founded in 2015 and headquartered in Nuremberg, Germany. It specializes in intelligent automation, providing services such as robotic process automation, personal robotic automation, and artificial intelligence solutions. With a presence in 24 cities across 15 countries and serving clients from diverse industries including industrial manufacturing, consumer goods, banking, insurance, and pharmaceuticals, Roboyo has established itself as a leader in hyperautomation professional services. The company employs a multidisciplinary team of strategists, technologists, and business analysts, including several recognized experts in the field. By focusing on solving complex technical challenges, Roboyo aims to deliver significant business outcomes for its clients, which include many Fortune 500 companies and notable firms from the DAX 40 index.

Noden Pharma

Acquisition in 2020
Noden Pharma is a global specialty pharmaceutical company dedicated to acquiring and providing prescription medicines across various therapeutic areas. The company holds exclusive worldwide rights to manufacture, market, and sell Tekturna and Tekturna HCT, which contain aliskiren, a direct renin inhibitor used for the treatment of hypertension. Noden Pharma aims to enhance the lives of patients by offering effective medical solutions in international markets.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.